Skip to main content

Change location

You are currently on the Luxembourg (English) website

My country is not on the list

Global

  • Bracco.com (English)

Asia

  • China (中文)
  • Japan (日本語)
  • South Korea (한국어)

Americas

  • Brazil (Português)
  • Canada (English)
  • Mexico (English)
  • Canada (Français)
  • USA (English)

Europe

  • Austria (English)
  • Belgium (English)
  • Czech Republic (English)
  • Denmark (English)
  • Finland (English)
  • France (Français)
  • Germany (Deutsch)
  • Iceland (English)
  • Italy (Italiano)
  • Luxembourg (English)
  • Norway (English)
  • Poland (English)
  • Slovakia (English)
  • Sweden (English)
  • Switzerland (English)
  • The Netherlands (English)
  • UK (English)
  • Careers
  • Media and News
  • Get in touch
    • Luxembourg (English)
  • Home
  • we are bracco
    We are Bracco

    Welcome to a World of contrasts

    • Our businesses
    • Purpose and values
    • Our history
    • Our Foundation
    • Responsibility and Ethical conduct
  • Our Portfolio

    Proven offerings for a proven difference

    • X-ray/CT
      • Contrast agents

        • Iomeron
      • Medical devices

        • Protoco2l Touch
        • CT Exprès
        • Empower CTA+
    • MRI
      • Contrast agents

        • MultiHance
        • ProHance
      • Medical Devices

        • Empower MR
    • Ultrasound
      • Contrast agents

        • Sonovue
    • Nuclear medicine
    • Interventional cardiology
      • Contrast agents

        • Iomeron
        • Iomeron 400
      • Medical devices

    • Digital solutions
    • Oncology
    • Cardiology
  • Woman looking into microscope
    Innovation

    A deep dive into our R&D progress

    • Digital future
    • R&D
    • The Bracco sites
    • Scientific heritage and patents
  • knowledge
    Knowledge

    Current activities and future opportunities

    • E-learning
    • Partnerships in education
    • Events
  • Ceriano Laghetto
    Sustainability

    Our game plan and goals for a better world

    • Our sustainability pillars
    • Governance and transparency
    • Sustainability report
  • Our Stories
  1. Home
  2. Our Portfolio
  3. MRI
  4. Contrast agents

  5. ProHance

ProHance® (Gadoteridol)

 

When Stability Matters 1, 2, 3, 4

 

ProHance® (gadoteridol) is a macrocyclic, non-ionic molecule chelated to a gadolinium ion, and it has a very low osmolality and viscosity5.

 

Due primarily to its macrocyclic structure, ProHance® possesses high in vitro stability2, 3.

 

Moreover, in recent clinical studies in patients undergoing total hip arthroplasty it has been shown that bone tissue retention of gadolinium was significantly higher in patients who received Omniscan than in those who received ProHance®. Approximately 2.5 times more gadolinium remained in femoral head bone after Omniscan than after ProHance® 4, 5.


The clinical experience with ProHance® exceeds 15 million doses administered worldwide6.

ProHance® is a gadolinium based, macrocyclic, non-ionic MR contrast agent first introduced in 1992. Since its launch ProHance® has established a strong record of safety and efficacy with millions of doses administered worldwide7. ProHance® has a high stability and the lowest osmolality among all contrast agents in its class, which maximize clinical utility and diagnostic confidence5.

 

ProHance® is a non-ionic contrast agent that does not interfere with a number of serum assays, including serum calcium determination8.

ProHance® provides low dissociation rate and high "in vivo" stability, reducing the risk of free gadolinium exposure2.

ProHance® has low viscosity, reducing pressure during high flow rate power injections5; also, it provides optimal injection comfort due to the low osmolality in case of very high rate of injection as in dynamic MR Imaging5.

ProHance® has high stability in virtue of the high chelate strength.

 

An in vivo study in rodents has shown that ProHance® releases the least amount of Gd in the body compared to gadopentetate, gadodiamide and gadoterate2.

Gibby et al., and White et al., showed that ProHance® leaves up to four times less gadolinium in human bones than gadodiamide3.

 

ProHance® has a full line of packaging options including unique solutions to optimize dosing protocols, reduce contrast waste, and increase operational efficiencies.

ProHance® is the only contrast agent in a 17 mL Pre Filled-Syringe (PFS) that offers exceptional dosing versatility and minimises contrast waste5.

ProHance® is also provided in large volumes (available in some markets) that increase dosing flexibility, minimise contrast waste and simplify inventory management5.

1) Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review.

 

Idée JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C.Fundam Clin Pharmacol. 2006 Dec;20(6):563-76. Review. Erratum in: Fundam Clin Pharmacol. 2007 Jun;21(3):335.

 

View

 

 

2) Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats.

 

Tweedle MF, Wedeking P, Kumar K.Invest Radiol. 1995 Jun;30(6):372-80.

 

View

 

 

3) Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy.

 

White GW, Gibby WA, Tweedle MF.Invest Radiol. 2006 Mar;41(3):272-8.

 

View

 

 

4) Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy.

 

Gibby WA, Gibby KA, Gibby WA.Invest Radiol. 2004 Mar;39(3):138-42.

 

View

 

 

5) ProHance® SPC

 

 

6) Data on file.

 

 

7) Bracco internal data.

 

 

8) Gadodiamide administration causes spurious hypocalcemia.

 

Prince MR, Erel HE, Lent RW, Blumenfeld J, Kent KC, Bush HL, Wang Y. Radiology. 2003 Jun;227(3):639-46.

 

View

ProHance_ PFS_PIL Summary of Products Characteristics_NL_FR 12/11/2023 pdf Download
ProHance_ PFS_ Summary of Products Characteristics_NL_FR 12/11/2023 pdf Download
ProHance_ VIALS_PIL Summary of Products Characteristics_FR 10/11/2024 pdf Download
ProHance_ VIALS_ Summary of Products Characteristics_FR 10/11/2024 pdf Download

PRODUCT SERVICES

 

If you have any questions regarding any Bracco Imaging product.

 

[email protected]

PROFESSIONAL SERVICES

 

The Professional Services Group is available to assist health care professionals with requests for scientific or medical information about Bracco Imaging products.

 

[email protected]

CUSTOMER SERVICES

 

For information on how to place an order or to contact Purchasing.

 

[email protected]

Contact us


Please fill out the form below and we will get back to you.

Different countries may have specific processes in place to handle reports of adverse reactions. To report an adverse reaction related to Bracco products, you can find specific contacts and information selecting the page "Pharmacovigilance" of your country.

I have read and I agree with the Bracco Privacy Policy

* I have read the BraccoHealthCare Professionals Privacy Notice and I consent to the processing of my personal data allowing Bracco Imaging SpA (Data Controller) to conduct its business or scientific operations and contact me with promotional communication through email, SMS, and other digital and offline channels, such as mobile apps and social media.

DISCLAIMER

 

For any product or type of product, whether a drug or device, referenced in this website, physicians should carefully review the product's package insert, instructions for use, or user manual prior to patient administration to ensure proper utilization of the product. The local Summaries of Product Characteristics of the main Bracco Imaging products are available on line.

 

Impaired renal function

 

There have been reports of nephrogenic systemic fibrosis (NSF) associated with use of some gadolinium-containing contrast agents in patients with severe renal impairment (GFR <30ml/min/1.73m2). As there is a possibility that NSF may occur with ProHance, it should only be used in these patients after careful consideration. Haemodialysis shortly after ProHance administration in patients currently receiving haemodialysis may be useful at removing Prohance from the body.

 

There is no evidence to support the initiation of haemodialysis for prevention or treatment of NSF in patients not already undergoing haemodialysis.

Please login to DocCheck
to view our products

Register here Forgot your password?

The Bracco Group is an international group of highly specialized companies.
We are an active part of the healthcare sector, and a global leader in diagnostic imaging.

  • We are Bracco
  • Our Portfolio
  • Innovation
  • Knowledge
  • Sustainability
  • Our Stories
  • Pharmacovigilance
  • Data Protection

Connect with us

Via Egidio Folli 50
20134 Milan, Italy
Phone + 39 02 2177.1

  • Terms of Use
  • Privacy Policy
  • Cookie Policy
  • Imprint
  • for Bracco VPN users

Bracco Copyright © 2025 | Registered office: Via E. Folli, 50, 20134 Milano, Italy | Share Capital € 104.000.000 f.p. | VAT Milan Comp. Reg. n. 00825120157 | Milan REA n. 348182